Last updated: 2026-09-09 19:19:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Tarsus Pharmaceuticals, Inc. (TARS) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $83.73, with a market capitalisation of $3.98B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $48.20 to $91.53. This page covers its latest market performance, valuation, price trends and company information.
$3.98B | |
$87.07 | |
$91.53 | |
$10.80 | |
$87.22 | |
340.67K | |
997.71K | |
-- | |
$91.53 | |
$48.20 | |
-- | |
-- |
Tarsus Pharmaceuticals, Inc. (TARS) is currently trading at $83.73 as of 2026-09-09 19:02:27, down 4.01% ($3.50) from the previous close of $87.22
During today's regular trading session, TARS has traded between $10.80 and $91.53, with a trading volume of 340.67K shares. The current price is near the upper end of today's range.
Over the past seven days, Tarsus Pharmaceuticals, Inc. (TARS) moved from $71.76 to $83.73, representing a gain of 16.67% ($11.96).
The stock traded between $70.71 and $91.53 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 1.14 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 82.0%
TARS is currently trading at $83.73, placing it 82.0% of the way from its 52-week low of $48.20 to its 52-week high of $91.53. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 370 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Tarsus Pharmaceuticals, Inc. (TARS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.